168 related articles for article (PubMed ID: 32987061)
1. Ensemble-based virtual screening in discovering potent inhibitors targeting Von Hippel-Lindau (VHL) E3 ubiquitin ligase.
Liu Y; Lei Y; Guo S; Zuo Z
Life Sci; 2020 Dec; 262():118495. PubMed ID: 32987061
[TBL] [Abstract][Full Text] [Related]
2. Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298).
Soares P; Gadd MS; Frost J; Galdeano C; Ellis L; Epemolu O; Rocha S; Read KD; Ciulli A
J Med Chem; 2018 Jan; 61(2):599-618. PubMed ID: 28853884
[TBL] [Abstract][Full Text] [Related]
3. Von Hippel-Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein.
Frost J; Rocha S; Ciulli A
J Biol Chem; 2021 Aug; 297(2):100910. PubMed ID: 34174286
[TBL] [Abstract][Full Text] [Related]
4. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction.
Buckley DL; Van Molle I; Gareiss PC; Tae HS; Michel J; Noblin DJ; Jorgensen WL; Ciulli A; Crews CM
J Am Chem Soc; 2012 Mar; 134(10):4465-8. PubMed ID: 22369643
[TBL] [Abstract][Full Text] [Related]
5. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
6. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.
Diehl CJ; Ciulli A
Chem Soc Rev; 2022 Oct; 51(19):8216-8257. PubMed ID: 35983982
[TBL] [Abstract][Full Text] [Related]
7. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.
Girardini M; Maniaci C; Hughes SJ; Testa A; Ciulli A
Bioorg Med Chem; 2019 Jun; 27(12):2466-2479. PubMed ID: 30826187
[TBL] [Abstract][Full Text] [Related]
8. An efficient strategy for digging protein-protein interactions for rational drug design - A case study with HIF-1α/VHL.
Xue X; Kang JB; Yang X; Li N; Chang L; Ji J; Meng XK; Zhang HQ; Zhong Y; Yu SP; Wu WY; Wang XL; Li NG; Sun SL
Eur J Med Chem; 2022 Jan; 227():113871. PubMed ID: 34638033
[TBL] [Abstract][Full Text] [Related]
9. QSAR modeling and in silico design of small-molecule inhibitors targeting the interaction between E3 ligase VHL and HIF-1α.
Pan J; Zhang Y; Ran T; Xu A; Qiao X; Yin L; Zhou W; Zhu L; Zhao J; Lu T; Chen Y; Jiang Y
Mol Divers; 2017 Aug; 21(3):719-739. PubMed ID: 28689235
[TBL] [Abstract][Full Text] [Related]
10. Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities.
Galdeano C; Gadd MS; Soares P; Scaffidi S; Van Molle I; Birced I; Hewitt S; Dias DM; Ciulli A
J Med Chem; 2014 Oct; 57(20):8657-63. PubMed ID: 25166285
[TBL] [Abstract][Full Text] [Related]
11. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.
Wang C; Zhang Y; Wang J; Xing D
Eur J Med Chem; 2022 Jan; 227():113906. PubMed ID: 34656901
[TBL] [Abstract][Full Text] [Related]
12. Role of the C-terminal alpha-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity.
Lewis MD; Roberts BJ
Oncogene; 2004 Mar; 23(13):2315-23. PubMed ID: 14691445
[TBL] [Abstract][Full Text] [Related]
13. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
[TBL] [Abstract][Full Text] [Related]
14. Expanding the Structural Diversity at the Phenylene Core of Ligands for the von Hippel-Lindau E3 Ubiquitin Ligase: Development of Highly Potent Hypoxia-Inducible Factor-1α Stabilizers.
Vu LP; Diehl CJ; Casement R; Bond AG; Steinebach C; Strašek N; Bricelj A; Perdih A; Schnakenburg G; Sosič I; Ciulli A; Gütschow M
J Med Chem; 2023 Sep; 66(18):12776-12811. PubMed ID: 37708384
[TBL] [Abstract][Full Text] [Related]
15. Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7.
Zoppi V; Hughes SJ; Maniaci C; Testa A; Gmaschitz T; Wieshofer C; Koegl M; Riching KM; Daniels DL; Spallarossa A; Ciulli A
J Med Chem; 2019 Jan; 62(2):699-726. PubMed ID: 30540463
[TBL] [Abstract][Full Text] [Related]
16. HIF-1alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases.
Paltoglou S; Roberts BJ
Oncogene; 2007 Jan; 26(4):604-9. PubMed ID: 16862177
[TBL] [Abstract][Full Text] [Related]
17. Drosophila von Hippel-Lindau tumor suppressor complex possesses E3 ubiquitin ligase activity.
Aso T; Yamazaki K; Aigaki T; Kitajima S
Biochem Biophys Res Commun; 2000 Sep; 276(1):355-61. PubMed ID: 11006129
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α.
Buckley DL; Gustafson JL; Van Molle I; Roth AG; Tae HS; Gareiss PC; Jorgensen WL; Ciulli A; Crews CM
Angew Chem Int Ed Engl; 2012 Nov; 51(46):11463-7. PubMed ID: 23065727
[TBL] [Abstract][Full Text] [Related]
19. Nitric oxide donor, (+/-)-S-nitroso-N-acetylpenicillamine, stabilizes transactive hypoxia-inducible factor-1alpha by inhibiting von Hippel-Lindau recruitment and asparagine hydroxylation.
Park YK; Ahn DR; Oh M; Lee T; Yang EG; Son M; Park H
Mol Pharmacol; 2008 Jul; 74(1):236-45. PubMed ID: 18426857
[TBL] [Abstract][Full Text] [Related]
20. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
